US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Cybin Inc. Common Shares
(NY:
CYBN
)
8.280
UNCHANGED
Last Price
Updated: 8:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc. Common Shares
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
41
42
Next >
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
April 13, 2022
From
Cybin Inc.
Via
Business Wire
Psychedelic Stock Gainers And Losers From April 11, 2022
↗
April 11, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.52% at $0.17
Via
Benzinga
Performance Comparisons Of The 5 Cannabis Sector Categories
↗
April 10, 2022
Here is a summary of how each of the 5 categories in the cannabis sector performed over four time periods, to highlight the different category trends that are underway.
Via
Talk Markets
Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today
↗
April 08, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.54% at $0.16
Via
Benzinga
WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies
↗
April 08, 2022
Cybin Inc. (NYSE: CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent ...
Via
Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position Of Psychedelic Programs
↗
April 08, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position of Psychedelic Programs
April 08, 2022
Via
Investor Brand Network
Topics
Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Further Strengthens Long-Term IP Position of Psychedelic-Based Programs
April 08, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space
April 08, 2022
Via
Investor Brand Network
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
April 08, 2022
From
Cybin Inc.
Via
Business Wire
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
↗
April 07, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.48% at $0.14
Via
Benzinga
Cybi (NEO: CYBN) (NYSE American: CYBN) To Participate In Benzinga Psychedelics Conference
↗
April 07, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Cybi (NEO: CYBN) (NYSE American: CYBN) to Participate in Benzinga Psychedelics Conference
April 07, 2022
Via
Investor Brand Network
Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today
↗
April 06, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 4.78% at $19.73 LOSERS:
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference
April 06, 2022
Via
Investor Brand Network
A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers
↗
April 06, 2022
From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE: CYBN) CEO, Doug Drysdale has certainly had an ...
Via
Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
↗
April 06, 2022
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.
Via
Benzinga
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
April 06, 2022
From
Cybin Inc.
Via
Business Wire
Psychedelic Stock Gainers And Losers From April 5, 2022
↗
April 05, 2022
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 1.60% at $1.27 LOSERS:
Via
Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
↗
April 04, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.06% at $14.18
Via
Benzinga
Cybin's (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
↗
April 04, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Cybin’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
April 04, 2022
Via
Investor Brand Network
3 Psychedelic Stocks to Buy for Oregon’s Magic Mushroom Bill
↗
April 04, 2022
Psychedelic medical treatments and therapies are gaining in popularity, and these psychedelic stocks could benefit as the market emerges.
Via
InvestorPlace
Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
April 01, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.26% at $0.86
Via
Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement Of Kernel Flow(R) Study
↗
April 01, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Inc. Achieves New Milestone
April 01, 2022
Via
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Study
April 01, 2022
Via
Investor Brand Network
March Update: Psychedelic Compounds-Based Drug Stocks Index Went Down -19%
↗
April 01, 2022
An update on the revisions that have been made to the Pure-Play Psychedelic Compounds-Based Drug Stocks Index with the increase in the minimum market capitalization required to be included in the...
Via
Talk Markets
Cybin Announces Additional Adelia Milestone Achievement
April 01, 2022
From
Cybin Inc.
Via
Business Wire
Field Trip Health, Revive Therapeutics Among Top Psychedelic Movers Of Today
↗
March 31, 2022
GAINERS: Intelgenx Technologies (OTC:IGXT) shares closed up 3.38% at $0.27
Via
Benzinga
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
41
42
Next >
